Vanguard Group Inc Cuts Holdings in Tetraphase Pharmaceuticals Inc (TTPH)

Share on StockTwits

Vanguard Group Inc decreased its holdings in shares of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) by 1.6% in the 3rd quarter, Holdings Channel reports. The firm owned 2,247,144 shares of the biopharmaceutical company’s stock after selling 37,672 shares during the period. Vanguard Group Inc’s holdings in Tetraphase Pharmaceuticals were worth $6,202,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also made changes to their positions in the business. BlackRock Inc. lifted its holdings in Tetraphase Pharmaceuticals by 3.4% during the 3rd quarter. BlackRock Inc. now owns 4,316,258 shares of the biopharmaceutical company’s stock valued at $11,914,000 after purchasing an additional 143,944 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Tetraphase Pharmaceuticals by 14.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,517,623 shares of the biopharmaceutical company’s stock valued at $6,949,000 after purchasing an additional 317,210 shares during the last quarter. Northern Trust Corp lifted its holdings in Tetraphase Pharmaceuticals by 3.5% during the 2nd quarter. Northern Trust Corp now owns 1,060,816 shares of the biopharmaceutical company’s stock valued at $3,787,000 after purchasing an additional 36,115 shares during the last quarter. Man Group plc lifted its holdings in Tetraphase Pharmaceuticals by 19.9% during the 3rd quarter. Man Group plc now owns 884,415 shares of the biopharmaceutical company’s stock valued at $2,441,000 after purchasing an additional 146,700 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Tetraphase Pharmaceuticals by 40.0% during the 3rd quarter. Renaissance Technologies LLC now owns 873,227 shares of the biopharmaceutical company’s stock valued at $2,410,000 after purchasing an additional 249,342 shares during the last quarter. 42.90% of the stock is owned by institutional investors and hedge funds.

Shares of TTPH traded up $0.02 during midday trading on Monday, reaching $1.20. 35,432 shares of the stock were exchanged, compared to its average volume of 579,037. Tetraphase Pharmaceuticals Inc has a twelve month low of $1.01 and a twelve month high of $5.68. The company has a market capitalization of $63.28 million, a P/E ratio of -0.46 and a beta of 2.89.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.02). Tetraphase Pharmaceuticals had a negative return on equity of 65.89% and a negative net margin of 432.40%. The firm had revenue of $1.15 million for the quarter, compared to analyst estimates of $2.09 million. As a group, sell-side analysts expect that Tetraphase Pharmaceuticals Inc will post -1.33 EPS for the current year.

Several equities research analysts have issued reports on TTPH shares. Zacks Investment Research downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, January 10th. B. Riley assumed coverage on Tetraphase Pharmaceuticals in a report on Friday, January 4th. They set a “buy” rating and a $3.00 target price for the company. Finally, Robert W. Baird reissued a “buy” rating and set a $3.00 target price on shares of Tetraphase Pharmaceuticals in a report on Monday, January 7th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $5.36.

TRADEMARK VIOLATION WARNING: “Vanguard Group Inc Cuts Holdings in Tetraphase Pharmaceuticals Inc (TTPH)” was originally posted by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://weekherald.com/2019/02/11/vanguard-group-inc-cuts-holdings-in-tetraphase-pharmaceuticals-inc-ttph.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Featured Story: Outstanding Shares

Want to see what other hedge funds are holding TTPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH).

Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply